News
Pfizer's inclacumab fails Phase III study for sickle cell disease, disappointing the community while the company remains ...
CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates Entered into ...
TipRanks on MSN4d
CureVac sees cash runway into 2028
Cash and cash equivalents amounted to EUR 392.7 million at the end of June 2025, decreasing from EUR 481.7 million at the end of 2024. In the ...
MONTCO Today on MSN6d
WSJ: GSK to Receive $370M in CureVac-BioNTech Vaccine Dispute
Glaxosmithkline, which has major operations in Montgomery County, is set to receive a major settlement, writes Anthony O. Goriainoff for the Wall Street Journal. The pharmaceutical powerhouse will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback